The University of Birmingham

Beecham Group Plc

British Technology Group Limited

Stichting Rega Vzw

Rega Instituut Vzw

Albert S Jones

Richard T Walker

Erik D De Clercq

Paul L Coe

Stewart A Noble

Gabriel A Verhelst

Philip J Barr

Compounds of formula I or a pharmaceutically acceptable salt thereof: ##STR1## in which formula R.sub.1 represents an aliphatic hydrocarbyl group; Ar represents a substituted or unsubstituted aromatic nucleus;

Antiviral compounds

The novel substance E-5-(2-bromovinyl)-2'-deoxyuridine and its corresponding iodovinyl derivative are gifted with specific antiviral activities towards herpes simplex virus. They may be synthesized by a condensation reaction followed by separation of anomers.

2'Deoxy-5-(2-halogenovinyl)-uridines, pharmaceutical compositions and

The compound of formula (I): ##STR1## wherein X is CFCl; and C.sub.1-6 alkanoyl esters and/or phosphate esters thereof, is active against herpes viruses.

Antiviral agents, their preparation and use

The invention relates to E-5-(2-halogenovinyl)-2'-deoxycytidines, e.g. E-5-(bromovinyl)-2'-deoxycytidine and E-5-(2-iodovinyl)-2'-deoxycytidine. These substances are endowed with specific antiviral activities towards herpes simplex virus and with an extremely low toxicity which makes them useful in antiviral medicines and for treatment of virus diseases in man and animal. They may be synthesized by introduction of an E-5-(2-halogenovinyl) sidechain into 2'-deoxycytidine, or by condensation of a trialkylsilyl derivative of E-5-(2-halogenovinyl)-cytosine with a hydroxyl-protected reactive derivative of 2'-deoxy-D-erythro-pentofuranose.

E-5-(2-Halogenovinyl)-2'-deoxycytidines

Growing community of inventors

Birmingham, United Kingdom

Albert S Jones